Isis Pharmaceuticals, Inc. (ISIS) Posts Q3 Loss of $0.27, Sales Miss Expectations
Tweet
Share
E-mailGet Alerts ISIS Hot Sheet
Join SI Premium – FREE
Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) reported Q3 EPS of ($0.27), $0.07 worse than the analyst estimate of ($0.20). Revenue for the quarter came in at $20.7 million versus the consensus estimate of $25.33 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
- Reading (RDI) Tops Q2 EPS by 4c
- Outlook Therapeutics (OTLK) Misses Q3 EPS by 9c
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
